ישראל - עברית - Ministry of Health

medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

ישראל - עברית - Ministry of Health

medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

ישראל - עברית - Ministry of Health

dover medical & scientific equipment ltd, israel - factor ix - אבקה וממס להכנת תמיסה להזרקה - factor ix 100 iu/ml - coagulation factor ix - coagulation factor ix - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

ישראל - עברית - Ministry of Health

dover medical & scientific equipment ltd, israel - factor ix - אבקה וממס להכנת תמיסה להזרקה - factor ix 100 iu/ml - coagulation factor ix - coagulation factor ix - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

ישראל - עברית - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - אבקה להכנת תמיסה לזריקה - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

ישראל - עברית - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - אבקה להכנת תמיסה לזריקה - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

ישראל - עברית - Ministry of Health

csl behring ltd., israel - factor xiii - powder for solution for injection - factor xiii 200 - 320 iu - coagulation factor xiii - coagulation factor xiii - congenital or acquired factor xiii deficiency, or to promote healing of wounds and bone fractures. congenital deficiency of factor xiii and resultant haemorrhagic syndroms

ישראל - עברית - Ministry of Health

csl behring ltd., israel - factor xiii - powder for solution for injection - factor xiii 1250 iu - coagulation factor xiii - coagulation factor xiii - congenital or acquired factor xiii deficiency or to promote healing of wounds and bone fractures. congenital deficiency of factor xiii and resultant haemorrhagic syndroms

ישראל - עברית - Ministry of Health

csl behring ltd., israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii (human) 500 iu / 10 ml; von willebrand factor 1200 iu / 10 ml - coagulation factor xiii - coagulation factor xiii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrands disease.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.